NHS vs private weight-loss treatment
NHS and private weight-loss treatment can involve the same medicines, but the way you reach care is different. NHS treatment is usually criteria-led and local. Private treatment is self-funded and easier to research online, but it should still include proper clinical checks, clear costs and follow-up care.
Different access, same need for safe checks
NHS can be the right first question
If your BMI, health conditions or medical history may put you in a higher-need group, ask what NHS assessment process applies locally.
Private can be easier to compare
Private services usually show prices, delivery and treatment options more openly, but they still need to decide whether treatment is suitable.
A careful comparison looks past speed
A quick consultation is not enough on its own. Check who reviews your details, what aftercare is included and what happens if treatment is paused or not suitable.
Start with the decision you are really making
If you may qualify for NHS care, it is worth understanding the local process before comparing private services. If you are looking privately, compare the care around the medicine as carefully as the medicine itself.
Ask about NHS access if...
You have weight-related health conditions, have already tried lifestyle support, need more joined-up care, or want to understand whether local NHS criteria might apply.
Compare private services if...
You want to understand self-pay options, prices, checks, delivery and follow-up before deciding whether to continue.
NHS care is shaped by criteria and local capacity
NHS England says tirzepatide can be prescribed through specialist weight-management services for eligible adults. Primary-care access is being phased, with early access focused on people with the highest clinical need.
For tirzepatide in primary care, NHS England describes an initial focus on people with BMI 40 or more, adjusted for ethnicity where relevant, plus at least four listed weight-related health problems. For Wegovy, specialist-service criteria can include BMI thresholds, weight-related health problems and local arrangements.
This is why NHS availability can feel confusing: national guidance, local rollout and individual clinical review all matter.
What changes in practice
Neither option is automatic. Compare the practical differences in cost, timing, checks and aftercare before you decide what to look at next.
| Compare | NHS | Private |
|---|---|---|
| Who can be assessed | Usually depends on local NHS services, national criteria and clinical priority. | Usually starts with an online questionnaire or clinic consultation, but treatment still depends on suitability. |
| Who pays | NHS-funded care may avoid private medicine costs, although standard NHS prescription charges can apply in England unless exempt. | You usually pay for the consultation, medicine, delivery and any review or aftercare costs. |
| Eligibility | Criteria can be stricter and may prioritise people with the highest clinical need, especially during phased rollout. | Private services may consider a wider group, but they still need to decide whether treatment is safe and appropriate. |
| Timing | Referral, local availability and waiting lists can affect how quickly an assessment happens. | Researching private care can be quicker, but checks, stock, dose availability and delivery still affect timing. |
| Treatment choice | The medicine offered depends on NHS guidance, local service arrangements and clinical judgement. | Private services may show more treatment choices, but the final decision should still follow a clinical review. |
| Aftercare | Care may include specialist weight-management support, dietetic input or wraparound care depending on the service. | Aftercare varies by service, so compare follow-up, contact options, dose reviews, restarts and side-effect advice. |
| Best question to ask | Which local NHS service or referral steps apply to me, and what criteria are being used now? | Who reviews my details, what is included in the total cost, and what help is available after starting? |
Check which questions may come up before treatment
This tool estimates BMI and highlights common access questions. It does not decide eligibility, prescribe treatment or replace advice from a qualified healthcare professional.
Private treatment should still feel clinically careful
A private service should explain who reviews your details, what health questions are asked, how identity and BMI may be checked, and what happens if treatment is not suitable. If a page makes treatment sound automatic, that is a reason to pause.
- Check the pharmacy, clinic, prescriber or company behind the service.
- Compare the total cost, including delivery, repeat checks and ongoing support.
- Look for clear advice on side effects, dose changes, pauses, restarts and stopping treatment.
Compare the whole care picture
NHS care may reduce direct medicine costs, but access can depend on referral, criteria and local services. Private care may be quicker to compare, but the visible medicine price is only one part of the monthly cost.
Choose what to check next
Eligibility guide
Read more about BMI, health conditions, pregnancy or breastfeeding, current medicines and assessment questions.
Private treatment
Compare self-pay service types, clinical checks, costs, delivery and ongoing support.
Safety and legitimacy
Check how to spot regulated providers, clear prescribing responsibility and safer online-service signals.
Comparison next step
Take the comparison into live route and provider context
The strongest next step is usually the provider shortlist, the treatment pages for each brand, and the main semaglutide guide rather than stopping at one verdict line.
Source checks
Cqc Online Primary Care Context
CQC online-primary-care guidance was reviewed for private online-service oversight context.
Checked: 27 April 2026 Confidence: High
Source: CQC: Online primary care services
Used to support cautious wording about online-service regulation and private-provider legitimacy checks.
NICE Tirzepatide Access Context
NICE tirzepatide guidance was reviewed for UK access context.
Checked: 27 April 2026 Confidence: High
Source: NICE TA1026: tirzepatide for managing overweight and obesity
Reviewed to explain staged UK access context around current weekly injection routes.
NICE Semaglutide Access Context
NICE semaglutide guidance was reviewed for UK access context.
Checked: 27 April 2026 Confidence: High
Source: NICE TA875: semaglutide for managing overweight and obesity
Reviewed to explain that national guidance and real-world access are related but not identical.
NHS Obesity Treatment Context
NHS guidance was reviewed for broad obesity treatment pathway context.
Checked: 27 April 2026 Confidence: High
Source: NHS: Treatment for obesity
Reviewed for cautious explanation of NHS pathways, treatment context and local-service differences.
Important information
This website is an informational comparison hub. It does not prescribe, supply or sell prescription-only medicines. Suitability depends on a regulated clinical assessment.
Some links may be affiliate or commercial links. Commercial relationships must not change the way safety, eligibility, source checks or editorial context are presented.